PARP3 comes to light as a prime target in cancer therapy.
Fiche publication
Date publication
mai 2019
Journal
Cell cycle (Georgetown, Tex.)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DANTZER Françoise
Tous les auteurs :
Rodriguez-Vargas JM, Nguekeu-Zebaze L, Dantzer F
Lien Pubmed
Résumé
Poly(ADP-ribose) polymerase 3 (PARP3) is the third member of the PARP family that catalyse a post-translational modification of proteins to promote, control or adjust numerous cellular events including genome integrity, transcription, differentiation, cell metabolism or cell death. In the late years, PARP3 has been specified for its primary functions in programmed and stress-induced double-strand break repair, chromosomal rearrangements, transcriptional regulation in the zebrafish and mitotic segregation. Still, deciphering the therapeutic value of its inhibition awaits additional investigations. In this review, we discuss the newest advancements on the specific functions of PARP3 in cancer aggressiveness exemplifying the relevance of its selective inhibition for cancer therapy.
Mots clés
Poly(ADP-ribose) polymerase 3/EMT/mTORC2, cancer aggressiveness
Référence
Cell Cycle. 2019 May 16;: